Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > A Realist From CEO.CA

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Jan 13, 2021 12:25pm

165 Views

Post# 32285406

RE:RE:RE:RE:RE:A Realist From CEO.CA

MikeStock wrote: That's certainly a good idea. Did you differentiate between the bashers and the people who occasionally vent? I'm certainly frustrated by the delays and the low volume but highly optimistic on the future. Seems like every time we bump up a little a bunch of people want out and we're right back to where we started.

All good Mike ... I think we'll eventually see the excitement return and share price rise.
Will see if JPM can start the new wave of interest prior to P3.
Most likely will happen, we just don't know when the tide turns.

Cheers all !!!

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December